Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease
Overview
Authors
Affiliations
Rationale: Exacerbations are important and heterogeneous events in the natural history of chronic obstructive pulmonary disease (COPD).
Objectives: To examine the consequences of prolonged exacerbation recovery in patients with COPD.
Methods: A cohort of 384 patients with COPD (FEV1 % predicted 45.8 [SD, 16.6] and a median exacerbation rate of 2.13 per year [interquartile range, 1.0-3.2]) were followed for 1,039 days (interquartile range, 660-1,814) between October 1995 and January 2013. Patients recorded daily worsening of respiratory symptoms and peak expiratory flow (PEF), and when stable underwent spirometry every 3 months, and completed the St. George's Respiratory Questionnaire annually. Exacerbations were diagnosed as 2 consecutive days with one major symptom plus another respiratory symptom. Exacerbation duration was defined as the time from onset to the day preceding 2 consecutive symptom-free days and recovery in PEF as return to preexacerbation levels.
Measurements And Main Results: A total of 351 patients had one or more exacerbations. Patients with a longer symptom duration (mean, 14.5 d) had a worse St. George's Respiratory Questionnaire total score (0.2 units per 1 day; P = 0.040). A longer symptomatic duration was associated with a shorter interval between exacerbation recovery and onset of the next exacerbation (hazard ratio, 1.004; P = 0.013). For 257 (7.3%) exacerbations, PEF did not recover within 99 days. These exacerbations were associated with symptoms of a viral infection (cold and sore throat). Patients with these nonrecovered exacerbations showed a 10.8 ml/yr (P < 0.001) faster decline in FEV1.
Conclusions: Prolonged exacerbation symptomatic duration is associated with poorer health status and a greater risk of a new event. Exacerbations where lung function does not recover are associated with symptoms of viral infections and accelerated decline in FEV1.
Paprocki M, Zwirowski S, Kuziemski K Sci Rep. 2025; 15(1):1969.
PMID: 39809919 PMC: 11732986. DOI: 10.1038/s41598-025-85388-2.
Exacerbations of bronchiectasis.
De Angelis A, Johnson E, Sutharsan S, Aliberti S Eur Respir Rev. 2024; 33(173).
PMID: 39048130 PMC: 11267293. DOI: 10.1183/16000617.0085-2024.
Increasing exercise capacity and physical activity in the COPD patient.
Kaur A, Bourbeau J, Brighton L, Celli B, Crouch R, Demeyer H Breathe (Sheff). 2024; 20(2):230347.
PMID: 38873235 PMC: 11167654. DOI: 10.1183/20734735.0347-2023.
Meldrum O, Donaldson G, Narayana J, Ivan F, Jaggi T, Mac Aogain M Am J Respir Crit Care Med. 2024; 210(3):298-310.
PMID: 38315959 PMC: 11348959. DOI: 10.1164/rccm.202306-1060OC.
Phenotypes, Etiotypes, and Endotypes of Exacerbations of Chronic Obstructive Pulmonary Disease.
Bhatt S, Agusti A, Bafadhel M, Christenson S, Bon J, Donaldson G Am J Respir Crit Care Med. 2023; 208(10):1026-1041.
PMID: 37560988 PMC: 10867924. DOI: 10.1164/rccm.202209-1748SO.